Aspect Medical Systems Secures Exclusive Rights to Commercialize New Brain Monitoring Technology for Depression

Business Wire, July 29, 2002

Certain statements about Aspect in this release and on Aspect's web site are forward-looking statements and may involve risks and uncertainties, including statements with respect to the development of new products and technologies in the area of neurodiagnostics, the benefits of, and demand and market acceptance for, Aspect's products and Aspect's competitive position. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are the results of clinical trials, market acceptance of products and products under development, regulatory approval of products under development, regulatory approval of requests for reimbursement, the scope of Aspect's patent protection and other risks included under the heading, "Factors Affecting Future Operating Results," in Aspect's Quarterly Report on Form 10-Q for the fiscal quarter ended March 30, 2002 filed on May 13, 2002, with the Securities and Exchange Commission. In addition, the statements in this press release represent Aspect's expectations and beliefs as of the date of this press release. Aspect anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while Aspect may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Aspect's expectations or beliefs as of any date subsequent to the date of this press release.

Bispectral Index and BIS are registered trademarks of Aspect Medical Systems, Inc. A-2000 is a trademark of Aspect Medical Systems, Inc. All other trademarks, service marks and company names are the property of their respective owners.